Companies Aveo Pharmaceuticals, Inc
Aveo Pharmaceuticals CEO salary & total pay, FY2021: $2.9M
Aveo Pharmaceuticals (AVEO) CEO salary, fiscal 2021: Michael Bailey was paid a salary of $589,959 and $2,943,905 in total compensation. Free brief. Every figure links to the company’s own filing.
Aveo Pharmaceuticals, Inc no longer files a proxy statement; its last pay data is FY2021.
Michael Bailey's complete compensation dossier
A PDF and a CSV sent to your email: Michael Bailey's pay in every fiscal year Aveo Pharmaceuticals, Inc reported it, line by line, with Michael Bailey's equity grants and Aveo Pharmaceuticals, Inc's disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $1,599,858FY2020
- $2,943,905FY2021
CEO total pay was $2,943,905 in fiscal 2021, up from $1,599,858 in fiscal 2020.
FY2021: salary $589,959 · bonus $0 · stock awards $0 · option awards $1,976,786
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Bailey | $589,959 | $0 | $0 | $1,976,786 | $308,254 | $0 | $68,906 | $2,943,905 |
| Chief Executive Officer | ||||||||
| Michael Needle | 416,409 | 0 | 0 | 718,570 | 0 | 0 | 272,297 | 1,407,276 |
| Chief Medical Officer | ||||||||
| Michael Ferraresso | 370,369 | 10,000 | 0 | 718,570 | 145,185 | 0 | 5,997 | 1,250,121 |
| Chief Commercial Officer | ||||||||
| Erick Lucera | 374,000 | 0 | 0 | 718,570 | 142,120 | 0 | 8,094 | 1,242,784 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2021 total | FY2020 total | FY2019 total | Δ FY2020→2021 |
|---|---|---|---|---|
| Michael Bailey | $2,943,905 | $1,599,858 | — | ↑ +1,344,047 |
| Michael Needle | 1,407,276 | 830,071 | — | ↑ +577,205 |
| Michael Ferraresso | 1,250,121 | 707,187 | — | ↑ +542,934 |
| Erick Lucera | 1,242,784 | 780,541 | — | ↑ +462,243 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our approach to executive compensation is guided by principles of holding executive officers accountable for long-term results, rewarding consistent strong execution, and establishing a clear connection between rewards and performance. We seek to achieve financial strength by linking compensation to performance goals and using equity as a key component of compensation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2021
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Michael Ferraresso | OPTION | 2021-02-05 | — | — | 100,000 | — | $718,570 |
| Michael Needle | OPTION | 2021-02-05 | — | — | 100,000 | — | 718,570 |
| Michael Bailey | OPTION | 2021-02-05 | — | — | 275,100 | — | 1,976,786 |
| Erick Lucera | OPTION | 2021-02-05 | — | — | 100,000 | — | 718,570 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Michael Ferraresso | $0 | $0 | $718,570 | 0.0% |
| Michael Needle | 0 | 0 | 718,570 | 0.0% |
| Michael Bailey | 0 | 0 | 1,976,786 | 0.0% |
| Erick Lucera | 0 | 0 | 718,570 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2021
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Erick Lucera | Option | 20,833 | 79,167 | 9.12 | — |
| Erick Lucera | Option | 23,952 | 26,048 | 6.7 | — |
| Michael Bailey | Option | 57,312 | 217,788 | 9.12 | — |
| Michael Bailey | Option | 55,462 | 65,562 | 5.6 | — |
| Michael Bailey | Option | 85,000 | 34,999 | 6.2 | — |
| Michael Bailey | Option | 95,832 | 4,167 | 30.8 | — |
| Michael Bailey | Option | 75,366 | — | 6 | — |
| Michael Bailey | Option | 46,000 | — | 10.8 | — |
| Michael Bailey | Option | 90,000 | — | 8.4 | — |
| Michael Bailey | Option | 16,750 | — | 15.7 | — |
| Michael Bailey | Option | 7,499 | — | 17.7 | — |
| Michael Bailey | Option | 11,999 | — | 25.1 | — |
| Michael Bailey | Option | 3,249 | — | 77.2 | — |
| Michael Bailey | Option | 3,100 | — | 131.8 | — |
| Michael Ferraresso | Option | 20,833 | 79,167 | 9.12 | — |
| Michael Ferraresso | Option | 19,471 | 23,028 | 5.6 | — |
| Michael Ferraresso | Option | 24,836 | 10,228 | 6.2 | — |
| Michael Ferraresso | Option | 3,593 | 156 | 30.8 | — |
| Michael Ferraresso | Option | 20,000 | — | 28.3 | — |
| Michael Needle | Option | 18,750 | — | 9.12 | — |
| Michael Needle | Option | 13,116 | — | 5.6 | — |
| Michael Needle | Option | 13,749 | — | 6.2 | — |
| Michael Needle | Option | 21,092 | — | 30.8 | — |
| Michael Needle | Option | 28,000 | — | 6 | — |
| Michael Needle | Option | 18,400 | — | 10.8 | — |
| Michael Needle | Option | 50,000 | — | 10.7 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Kenneth BateIndependent · Board Chair · Audit (Chair) · Nominating and Governance | $88,379 | — | $70,355 | — | — | $158,734 |
| Corinne EpperlyIndependent · Compensation · Nominating and Governance | 48,888 | — | 99,360 | — | — | 148,248 |
| Kevin CullenIndependent · Audit · Compensation | 36,663 | — | 98,935 | — | — | 135,598 |
| Anthony EvninIndependent · Nominating and Governance (Chair) · Audit | 57,258 | — | 70,355 | — | — | 127,613 |
| Scarlett SpringIndependent · Audit · Compensation (Chair) | 56,484 | — | 70,355 | — | — | 126,839 |
| Gregory MayesIndependent · Compensation · Nominating and Governance | 50,250 | — | 70,355 | — | — | 120,605 |
| Robert YoungIndependent · Not standing for re-election · Departed during FY | 24,365 | — | 0 | — | — | 24,365 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,500 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 16,000 / 12,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2021 |
|---|---|
| Cash retainers and fees | $362,287 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $362,287 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Aveo Pharmaceuticals as a peer
Companies that benchmark against AVEO
No companies currently name AVEO as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2021
The peer group as the company's own proxy names it, the “2022 peer group” — the reference set behind the percentile above.
Peer reciprocity
The companies Aveo Pharmaceuticals, Inc names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Eagle Pharmaceuticals, Inc. | 2022 | Scott Tarriff | $848,940 | $9,011,197 | $0 | $636,705 | $10,520,577 |
| 2 | Geron Corporation | 2025 | Harout Semerjian | 321,538 | 0 | 9,695,400 | 203,000 | 10,221,755 |
| 3 | Syndax Pharmaceuticals, Inc. | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 4 | Akebia Therapeutics, Inc. | 2025 | John Butler | 864,010 | 2,164,338 | 2,024,798 | 580,973 | 5,652,339 |
| 5 | Xeris Biopharma Holdings, Inc. | 2025 | John Shannon | 742,334 | 2,848,000 | 838,615 | 607,971 | 5,042,584 |
| 6 | Aldeyra Therapeutics, Inc. | 2025 | Todd Brady | 700,000 | 0 | 3,801,379 | 189,000 | 4,704,179 |
| 7 | Rigel Pharmaceuticals, Inc. | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 8 | Intercept Pharmaceuticals, Inc. | 2022 | Jerome Durso | 714,813 | 2,547,438 | 535,540 | 634,552 | 4,455,463 |
| 9 | UroGen Pharma, Ltd. | 2025 | Elizabeth Barrett | 855,590 | 2,122,211 | 0 | 516,263 | 4,310,624 |
| 10 | Corbus Pharmaceuticals Holdings, Inc. | 2025 | Yuval Cohen | 646,566 | 666,699 | 2,039,294 | 0 | 3,750,125 |
| 11 | Esperion Therapeutics, Inc. | 2025 | Sheldon Koenig | 770,833 | 1,260,000 | 847,929 | 639,375 | 3,535,512 |
| 12 | Aquestive Therapeutics, Inc. | 2025 | Daniel Barber | 659,885 | 1,547,342 | 877,200 | 409,132 | 3,493,559 |
| 13 | G1 Therapeutics, Inc. | 2023 | John Bailey | 794,976 | 1,392,022 | 666,209 | 387,551 | 3,250,658 |
| 14 | Puma Biotechnology, Inc. | 2025 | Alan Auerbach | 931,333 | 551,549 | 535,513 | 1,027,307 | 3,062,337 |
| 15 | Aveo Pharmaceuticals, Inc | 2021 | Michael Bailey | 589,959 | 0 | 1,976,786 | 308,254 | 2,943,905 |
| 16 | X4 Pharmaceuticals, Inc. | 2025 | Paula Ragan | 420,170 | 1,081,575 | 0 | 0 | 2,640,569 |
| 17 | Oncocyte Corporation | 2025 | Joshua Riggs | 472,293 | 599,999 | 1,332,000 | 0 | 2,594,786 |
| 18 | Isoray, Inc. | 2025 | Johan Spoor | 680,000 | 0 | 1,302,692 | 408,000 | 2,404,692 |
| 19 | Verastem, Inc. | 2025 | Daniel Paterson | 674,000 | 1,161,661 | 0 | 489,324 | 2,349,975 |
| 20 | Karyopharm Therapeutics Inc. | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 21 | Actinium Pharmaceuticals, Inc. | 2025 | Sandesh Seth | 762,320 | 0 | 0 | 0 | 1,187,320 |
| 22 | MEI Pharma, Inc. | 2025 | David Urso | 53,528 | 0 | 0 | 0 | 934,046 |
| 23 | Aytu BioPharma, Inc. | 2026 | Joshua Disbrow | 608,154 | 42,750 | 0 | 177,000 | 844,854 |
| — | Clovis Oncology, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Aprea Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Strongbridge Biopharma plc | — | — | — | — | — | — | not in coverage universe |
| — | Calithera Biosciences, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Idera Pharmaceuticals, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Casi Pharmaceuticals, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Aveo Pharmaceuticals, Inc | not disclosed | Option 100 | not disclosed | Aon |
| Actinium Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | StreeterWyatt Analytics LLC |
| Akebia Therapeutics, Inc. | 90% | Options 50 · RSU 25 · MSU 25 | No | Pearl Meyer |
| Aldeyra Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Aprea Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Aquestive Therapeutics, Inc. | not disclosed | Options 42 · PSU 30 · RSU 28 | No | Aon |
| Aytu BioPharma, Inc. | 50% | not disclosed | not disclosed | Alvarez and Marsal Holdings, LLC |
| Calithera Biosciences, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Casi Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Clovis Oncology, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Corbus Pharmaceuticals Holdings, Inc. | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| Eagle Pharmaceuticals, Inc. | 75% | PSU 75 · RSU 25 | Yes — Total Shareholder Return (TSR) relative to S&P 600 Biotech Select Index (rTSR) | Compensia |
| Esperion Therapeutics, Inc. | 110% | not disclosed | not disclosed | not disclosed |
| G1 Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford, Aon’s Human Capital Solutions Practice |
| Geron Corporation | 90% | Options 75 · RSU 25 | not disclosed | Aon |
| Idera Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Intercept Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon plc's Rewards Solution practice (Radford) |
| Isoray, Inc. | 100% | Options 100 | not disclosed | Aon |
| Karyopharm Therapeutics Inc. | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| MEI Pharma, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Oncocyte Corporation | not disclosed | not disclosed | not disclosed | Frederic W. Cook & Co., Inc. |
| Puma Biotechnology, Inc. | 169.7% | Options 50 · RSU 50 | not disclosed | Compensia |
| Rigel Pharmaceuticals, Inc. | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
| Strongbridge Biopharma plc | not disclosed | not disclosed | not disclosed | not disclosed |
| Syndax Pharmaceuticals, Inc. | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| UroGen Pharma, Ltd. | 80% | RSU 50 · PSU 50 | No | Compensia, Inc. |
| Verastem, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| X4 Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Xeris Biopharma Holdings, Inc. | 125% | not disclosed | not disclosed | Aon Consulting, Inc. |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2020 | 2020-06-10 | 4,480,153 | 779,438 | 83,331 | 85.18% | Passed |
| 2019 | 2019-06-12 | 44,043,407 | 15,566,550 | 874,330 | 73.89% | Passed |
| 2018 | 2018-06-18 | 48,704,579 | 783,037 | 282,566 | 98.42% | Passed |
| 2017 | 2017-06-21 | 51,716,387 | 857,651 | 123,849 | 98.37% | Passed |
| 2016 | 2016-05-26 | 18,201,331 | 496,243 | 145,673 | 97.35% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2020 | 2020-06-10 | 85.18%a |
| 2019 | 2019-06-12 | 73.89%b |
| 2018 | 2018-06-18 | 98.42%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 11 : 1 |
|---|---|
| CEO total compensation | $2,943,905 |
| Median employee compensation | $278,596 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2021 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Erick Lucera | Chief Financial Officer | 2023-01-19 | D | 218,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Erick Lucera | Chief Financial Officer | 2023-01-19 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Erick Lucera | Chief Financial Officer | 2023-01-19 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Bailey | Director | 2023-01-19 | D | 625,192 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Bailey | Director | 2023-01-19 | D | 275,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Bailey | Director | 2023-01-19 | D | 35,302 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Bailey | Director | 2023-01-19 | D | 93,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Bailey | Director | 2023-01-19 | D | 16,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Bailey | Director | 2023-01-19 | D | 99,999 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Bailey | Director | 2023-01-19 | D | 75,366 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Bailey | Director | 2023-01-19 | D | 46,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Bailey | Director | 2023-01-19 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Bailey | Director | 2023-01-19 | D | 7,499 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Bailey | Director | 2023-01-19 | D | 11,999 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Bailey | Director | 2023-01-19 | D | 3,249 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Bailey | Director | 2023-01-19 | D | 333,167 | 15 | 4,997,505 | Common | Form 4 ↗ |
| Mayes, Gregory T. | Director | 2023-01-19 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mayes, Gregory T. | Director | 2023-01-19 | D | 12,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mayes, Gregory T. | Director | 2023-01-19 | D | 4,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mayes, Gregory T. | Director | 2023-01-19 | D | 10,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scarlett Spring | Director | 2023-01-19 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scarlett Spring | Director | 2023-01-19 | D | 12,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scarlett Spring | Director | 2023-01-19 | D | 4,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scarlett Spring | Director | 2023-01-19 | D | 10,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Cullen | Director | 2023-01-19 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Cullen | Director | 2023-01-19 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Corinne Epperly | Director | 2023-01-19 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Corinne Epperly | Director | 2023-01-19 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Corinne Epperly | Director | 2023-01-19 | D | 10,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Ferraresso | Chief Commercial Officer | 2023-01-19 | D | 220,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Ferraresso | Chief Commercial Officer | 2023-01-19 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Ferraresso | Chief Commercial Officer | 2023-01-19 | D | 42,499 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Ferraresso | Chief Commercial Officer | 2023-01-19 | D | 35,064 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Ferraresso | Chief Commercial Officer | 2023-01-19 | D | 3,749 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Ferraresso | Chief Commercial Officer | 2023-01-19 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Ferraresso | Chief Commercial Officer | 2023-01-19 | D | 16,345 | 15 | 245,175 | Common | Form 4 ↗ |
| Jebediah Ledell | Chief Operating Officer | 2023-01-19 | D | 27,702 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jebediah Ledell | Chief Operating Officer | 2023-01-19 | D | 170,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony Evnin | Director | 2023-01-19 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony Evnin | Director | 2023-01-19 | D | 12,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony Evnin | Director | 2023-01-19 | D | 4,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony Evnin | Director | 2023-01-19 | D | 4,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony Evnin | Director | 2023-01-19 | D | 4,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony Evnin | Director | 2023-01-19 | D | 7,785 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony Evnin | Director | 2023-01-19 | D | 6,402 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony Evnin | Director | 2023-01-19 | D | 2,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony Evnin | Director | 2023-01-19 | D | 2,515 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony Evnin | Director | 2023-01-19 | D | 1,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony Evnin | Director | 2023-01-19 | D | 1,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anthony Evnin | Director | 2023-01-19 | D | 41,841 | 15 | 627,615 | Common | Form 4 ↗ |
| Kenneth Bate | Director | 2023-01-19 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2023-01-19 | D | 12,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2023-01-19 | D | 4,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2023-01-19 | D | 4,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2023-01-19 | D | 4,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2023-01-19 | D | 7,785 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2023-01-19 | D | 6,402 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2023-01-19 | D | 2,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2023-01-19 | D | 2,515 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2023-01-19 | D | 1,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2023-01-19 | D | 1,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2023-01-19 | D | 375 | 15 | 5,625 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (108 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Michael Bailey. DEF 14A, filed 2022-04-26. Section “Summary Compensation Table” · page 47. As printed: 2,943,905. View filing ↗
- Section 01, Michael Needle. DEF 14A, filed 2022-04-26. Section “Summary Compensation Table” · page 47. As printed: 1,407,276. View filing ↗
- Section 01, Michael Ferraresso. DEF 14A, filed 2022-04-26. Section “Summary Compensation Table” · page 47. As printed: 1,250,121. View filing ↗
- Section 01, Erick Lucera. DEF 14A, filed 2022-04-26. Section “Summary Compensation Table” · page 47. As printed: 1,242,784. View filing ↗
- Section 03, Michael Ferraresso OPTION. DEF 14A, filed 2022-04-26. Section “Grants of Plan-Based Awards for the Year Ended December 31, 202” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Needle OPTION. DEF 14A, filed 2022-04-26. Section “Grants of Plan-Based Awards for the Year Ended December 31, 202” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Bailey OPTION. DEF 14A, filed 2022-04-26. Section “Grants of Plan-Based Awards for the Year Ended December 31, 202” · grants of plan-based awards table. View filing ↗
- Section 03, Erick Lucera OPTION. DEF 14A, filed 2022-04-26. Section “Grants of Plan-Based Awards for the Year Ended December 31, 202” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2022-04-26. Section “CEO Pay Ratio”. As printed: 11 : 1. View filing ↗
- Section 08, Kenneth Bate. DEF 14A, filed 2022-04-26. Section “Director Compensation”. As printed: 158,734. View filing ↗
- Section 08, Corinne Epperly. DEF 14A, filed 2022-04-26. Section “Director Compensation”. As printed: 148,248. View filing ↗
- Section 08, Kevin Cullen. DEF 14A, filed 2022-04-26. Section “Director Compensation”. As printed: 135,598. View filing ↗
- Section 08, Anthony Evnin. DEF 14A, filed 2022-04-26. Section “Director Compensation”. As printed: 127,613. View filing ↗
- Section 08, Scarlett Spring. DEF 14A, filed 2022-04-26. Section “Director Compensation”. As printed: 126,839. View filing ↗
- Section 08, Gregory Mayes. DEF 14A, filed 2022-04-26. Section “Director Compensation”. As printed: 120,605. View filing ↗
- Section 08, Robert Young. DEF 14A, filed 2022-04-26. Section “Director Compensation”. As printed: 24,365. View filing ↗
- Section 02, Erick Lucera 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Erick Lucera 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Erick Lucera 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mayes, Gregory T. 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mayes, Gregory T. 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mayes, Gregory T. 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mayes, Gregory T. 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scarlett Spring 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scarlett Spring 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scarlett Spring 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scarlett Spring 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Cullen 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Cullen 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Corinne Epperly 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Corinne Epperly 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Corinne Epperly 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Ferraresso 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Ferraresso 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Ferraresso 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Ferraresso 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Ferraresso 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Ferraresso 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Ferraresso 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jebediah Ledell 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jebediah Ledell 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2020 vote. Form 8-K, filed 2020-06-10. Item 5.07 · say-on-pay result. As reported: 85.18% (votes for as printed: 4,480,153). View filing ↗
- Section 06, 2019 vote. Form 8-K, filed 2019-06-13. Item 5.07 · say-on-pay result. As reported: 73.89% (votes for as printed: 44,043,407). View filing ↗
- Section 06, 2018 vote. Form 8-K, filed 2018-06-21. Item 5.07 · say-on-pay result. As reported: 98.42% (votes for as printed: 48,704,579). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 362,287 + equity 0 + all other 0 = 362,287, summed across the director compensation table rows.
- Eagle Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2023-05-01. CEO total compensation as printed in Eagle Pharmaceuticals, Inc.'s own proxy. As printed: 10,520,577. View filing ↗
- Geron Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Geron Corporation's own proxy. As printed: 10,221,755. View filing ↗
- Syndax Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals, Inc.'s own proxy. As printed: 7,089,213. View filing ↗
- Akebia Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Akebia Therapeutics, Inc.'s own proxy. As printed: 5,652,339. View filing ↗
- Xeris Biopharma Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Xeris Biopharma Holdings, Inc.'s own proxy. As printed: 5,042,584. View filing ↗
- Aldeyra Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Aldeyra Therapeutics, Inc.'s own proxy. As printed: 4,704,179. View filing ↗
- Rigel Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. View filing ↗
- Intercept Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2023-05-01. CEO total compensation as printed in Intercept Pharmaceuticals, Inc.'s own proxy. As printed: 4,455,463. View filing ↗
- UroGen Pharma, Ltd., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in UroGen Pharma, Ltd.'s own proxy. As printed: 4,310,624. View filing ↗
- Corbus Pharmaceuticals Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Corbus Pharmaceuticals Holdings, Inc.'s own proxy. As printed: 3,750,125. View filing ↗
- Esperion Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Esperion Therapeutics, Inc.'s own proxy. As printed: 3,535,512. View filing ↗
- Aquestive Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Aquestive Therapeutics, Inc.'s own proxy. As printed: 3,493,559. View filing ↗
- G1 Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in G1 Therapeutics, Inc.'s own proxy. As printed: 3,250,658. View filing ↗
- Puma Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Puma Biotechnology, Inc.'s own proxy. As printed: 3,062,337. View filing ↗
- Aveo Pharmaceuticals, Inc (subject), Section 10b CEO total. DEF 14A, filed 2022-04-26. CEO total compensation as printed in Aveo Pharmaceuticals, Inc's own proxy. As printed: 2,943,905. View filing ↗
- X4 Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in X4 Pharmaceuticals, Inc.'s own proxy. As printed: 2,640,569. View filing ↗
- Oncocyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Oncocyte Corporation's own proxy. As printed: 2,594,786. View filing ↗
- Isoray, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Isoray, Inc.'s own proxy. As printed: 2,404,692. View filing ↗
- Verastem, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Verastem, Inc.'s own proxy. As printed: 2,349,975. View filing ↗
- Karyopharm Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics Inc.'s own proxy. As printed: 2,320,902. View filing ↗
- Actinium Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-16. CEO total compensation as printed in Actinium Pharmaceuticals, Inc.'s own proxy. As printed: 1,187,320. View filing ↗
- MEI Pharma, Inc., Section 10b CEO total. DEF 14A, filed 2025-12-30. CEO total compensation as printed in MEI Pharma, Inc.'s own proxy. As printed: 934,046. View filing ↗
- Aytu BioPharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-22. CEO total compensation as printed in Aytu BioPharma, Inc.'s own proxy. As printed: 844,854. View filing ↗
- Section 10a, G1 Therapeutics, Inc. reciprocity. DEF 14A. G1 Therapeutics, Inc. names Aveo Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗